Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
Sign up today and learn more about Prelude Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Prelude Stock
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Board of Director
Chief Commercial Officer